This "is something that pharmaceutical industry has de-emphasized just because of the way things have evolved," said Sulikowski. "And that's one of our advantages, in that we have expertise in natural products as well as medicinal chemistry."
Cancer drug development poses many challenges but also unique opportunities.
"There is a difficulty in that cancer is not a single disease; it's a family of loosely related diseases," said Waterson. "There's an opportunity for a whole myriad of different treatments that are pretty much only tailored to a small subset of people, where your treatment addresses their specific need."
A unique aspect of the CBC is the NCI's efforts to establish intellectual property rights for investigators and institutions that develop assays or drug candidates.
"The hope is that by recognizing establishment of intellectual property as one of the goals, they will attract people with the best ideas, things that really might be able to become a drug," said Waterson.
Vanderbilt's involvement with the CBC, along with the recent arrival of Stephen Fesik, Ph.D., who previously led cancer drug discovery efforts at Abbott Laboratories, will make Vanderbilt "one of the best academic institutions doing cancer drug discovery in the country," Marnett said.
Other Vanderbilt investigators involved in this effort include:
Other sites participating in the CBC are:
| Contact: Melissa Marino melissa.marino@vanderbilt.edu 615-322-4747 Vanderbilt University Medical Center Source:Eurekalert |